与肥胖相关的人类肝脏和脏中药物载体表达的改变
Katarzyna Kosicka-Noworzyń1,2, Aleksandra Romaniuk-Drapała3,4, Yi-Hua Sheng4,5
1Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3, Poznań, 60-806, Poland. kasiakosicka@ump.edu.pl.
Pharmacological reports : PR
|October 16, 2024
概括
肥胖会改变肝脏和脏中的药物载体基因表达,可能会影响药物的药理动力学 (PK). 需要进一步的研究来证实这些发现在患者身上.
科学领域:
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
- 生理学 生理学 生理学
背景情况:
- 与肥胖相关的病理生理变化可能会影响药物药理动力学 (PK).
- 肝脏和脏运输体对于药物清除和消除至关重要.
- 了解身体质量指数 (BMI) 如何影响传递器功能对于药物剂量至关重要.
研究的目的:
- 研究超重和肥胖对脏和肝脏药物载体基因表达的影响.
- 为了确定受改变BMI影响的特定载体.
主要方法:
- 人类肝脏和脏样本从瘦肉 (BMI < 25 kg/m2) 和超重/肥胖 (BMI ≥ 25 kg/m2) 个体中收集.
- 用实时定量PCR分析了84种药物载体的基因表达.
主要成果:
- 在超重/肥胖的人群中观察到脏和肝脏药物载体基因表达的显著变化.
- 肝脏组织显示ABCC4.4的上调调节.
- 脏组织表现出ABCC10的上调和ABCA1,ABCC3和SLC15A1.1的下调.
结论:
- 观察到的基因表达变化可能解释了瘦身和肥胖个体之间药物PK的差异.
- 需要进一步的蛋白质和功能研究来验证这些研究结果在患者群体中.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
33
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
33
Hepatic Drug Clearance: Role of Transporters
42
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
42
Nonlinear Pharmacokinetics: Role of Transporters
38
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
38
Carrier-Mediated Transport
281
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
281
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Factors Affecting Drug Biotransformation: Biological
123
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
123


